Safety profile of pressurized intraperitoneal aerosol chemotherapy in the treatment of ovarian cancer

Close metadata

OBJECTIVE

Assessment of the safety profile and adverse events in women with newly diagnosed ovarian cancer and peritoneal carcinomatosis using two-component chemotherapy, including pressurized intraperitoneal aerosol chemotherapy, after surgical cytoreduction.

MATERIAL AND METHODS

The study included 164 patients with morphologically verified peritoneal carcinomatosis. All the women were divided into two groups.

The distribution of patients into groups was carried out during cytoreductive surgery using a digital online randomizer. The first group of the study (the main one) included patients (n=79) who underwent intra-abdominal aerosol chemotherapy under pressure immediately after the completion of the cytoreductive stage of the operation within one surgical intervention and after 1.5 months, as well as courses of polychemotherapy. The second group (n=85) included women who underwent surgical treatment and polychemotherapy. In both observation groups, all adverse events were recorded according to the criteria of the Common Terminology Criteria for Adverse Events (CTCAE).

RESULTS

In the first group of patients during the analyzed time period, a total of 237 courses of PCT and 151 PIPAC sessions were conducted, while we registered 170 (71.7%) cases of adverse events. In the second group, 255 courses of systemic PCT were conducted at the end of the observation. At the same time, 184 (72.1%) episodes of the development of adverse events of a toxicological profile were registered. In none of the women from the first and second observation groups did we record the presence of adverse events of the 4^th degree of severity. There were no statistically significant differences between the comparison groups regarding the occurrence of adverse events.

CONCLUSION

At the intermediate stage of a prospective controlled randomized trial, it was possible to establish a favorable safety profile of intraperitoneal aerosol chemotherapy under pressure, used in addition to the standard combined treatment of newly diagnosed ovarian cancer with peritoneal carcinomatosis.

Keywords:

ovarian cancer

ascites

peritoneal carcinomatosis

Peritoneal Cancer Index (PCI)

pressurized intraperitoneal aerosol chemotherapy

safety profile

adverse events

complications

Authors:

Dzasokhov A.S.

Moscow Regional Oncological Dispensary

ORCID: 0000-0003-4977-3533

Kostin A.A.

Peoples’ Friendship University of Russia named after Patrice Lumumba

ORCID: 0000-0002-0792-6012

Astashov V.L.

Moscow Regional Oncological Dispensary

ORCID: 0000-0003-1075-3797

Turiev A.V.

Moscow Regional Oncological Dispensary

ORCID: 0000-0001-9284-4873

Kuchuk A.V.

Peoples’ Friendship University of Russia named after Patrice Lumumba

ORCID: 0000-0002-3807-1352

Received:

07.06.2023

Accepted:

16.11.2023

List of references:

Račkauskas R, Baušys A, Lukšta M, Jurgaitis J, Paškonis M, Strupas K. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) for peritoneal malignancy: initial experience of the first program in the Baltic countries. World J Surg Oncol. 2021;19(1):236. https://doi.org/10.1186/s12957-021-02357-5
Kurtz F, Struller F, Horvath P, Solass W, Bösmüller H, Königsrainer A, Reymond MA. Feasibility, safety, and efficacy of pressurized intraperitoneal aerosol chemotherapy (PIPAC) for peritoneal metastasis: a Registry Study. Gastroenterol Res Pract. 2018;2018:2743985. https://doi.org/10.1155/2018/2743985
GOST R 52379-2005. Gruppa R26. Natsional’nyi standart Rossiiskoi Federatsii. Nadlezhashchaya klinicheskaya praktika. Good Clinical Practice (GCP). OKS 11.120 19.020. OKP 93 1000 - 93 7000. 2006. (In Russ.).
Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240(2):205-213. https://doi.org/10.1097/01.sla.0000133083.54934.ae
Clavien PA, Barkun J, de Oliveira ML, Vauthey JN, Dindo D, Schulick RD, de Santibañes E, Pekolj J, Slankamenac K, Bassi C, et al. The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg. 2009;250(2):187-196. https://doi.org/10.1097/SLA.0b013e3181b13ca2
Gilbert L, Oaknin A, Matulonis UA, Mantia-Smaldone GM, Lim PC, Castro CM, Provencher D, Memarzadeh S, Method M, Wang J, et al. Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer. Gynecol Oncol. 2023;170:241-247. https://doi.org/10.1016/j.ygyno.2023.01.020
Gantsev ShKh, Moiseenko VM, Gantsev KSh, Solomennyi SV, Kzyrgalin ShR, Dokichev VA, Moiseenko FV, Minigazimov RS. Mineralization of the peritoneum - a new target in the treatment of peritoneal carcinomatosis. Creative Surgery and Oncology. 2018;8(4):279-284. (In Russ.). https://doi.org/10.24060/2076-3093-2018-8-4-279-284
Stewart C, Ralyea C, Lockwood S. Ovarian cancer: an integrated review. Semin Oncol Nurs. 2019;35(2):151-156. https://doi.org/10.1016/j.soncn.2019.02.001
Blanco A, Giger-Pabst U, Solass W, Zieren J, Reymond MA. Renal and hepatic toxicities after pressurized intraperitoneal aerosol chemotherapy (PIPAC). Ann Surg Oncol. 2013;20(7):2311-2316. https://doi.org/10.1245/s10434-012-2840-2
Tempfer CB, Solass W, Reymond MA. Pressurized intraperitoneal chemotherapy (PIPAC) in women with gynecologic malignancies: a review. Wien Med Wochenschr. 2014;164(23-24):519-528. https://doi.org/10.1007/s10354-014-0312-y
Dzasokhov AS, Kostin AA, Astashov VL. Sposob lecheniya peritoneal’nogo kantseromatoza pri rake yaichnikov. Patent na izobretenie RU 2745478 C1. 2021. (In Russ.).
Solass W, Giger-Pabst U, Zieren J, Reymond MA. Pressurized intraperitoneal aerosol chemotherapy (PIPAC): occupational health and safety aspects. Ann Surg Oncol. 2013;20(11):3504-3511. https://doi.org/10.1245/s10434-013-3039-x
Tempfer CB, Celik I, Solass W, Buerkle B, Pabst UG, Zieren J, Strumberg D, Reymond MA. Activity of pressurized intraperitoneal aerosol chemotherapy (PIPAC) with cisplatin and doxorubicin in women with recurrent, platinum-resistant ovarian cancer: preliminary clinical experience. Gynecol Oncol. 2014;132(2):307-311. https://doi.org/10.1016/j.ygyno.2013.11.022
Dzasokhov AS, Kostin AA, Astashov VL, Turiev AV, Uskov AD. The effect of pressurised intraperitoneal aerosol chemotherapy on the quality of life of patients with primary diagnosed ovarian cancer with peritoneal carcinomatosis during combined treatment. Research and Practical Medicine Journal. 2023;10(1):68-77. (In Russ.). https://doi.org/10.17709/2410-1893-2023-10-1-6
U.S. Department of health and human services. Common Terminology Criteria for Adverse Events (CTCAE). Version 5.0. 2017. Available at: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_5x7.pdf
Bristow RE, Puri I, Chi DS. Cytoreductive surgery for recurrent ovarian cancer: a meta-analysis. Gynecol Oncol. 2009;112(1):265-274. https://doi.org/10.1016/j.ygyno.2008.08.033
Macrì A, Fortugno A, Saladino E. Rationale and techniques of cytoreductive surgery and peritoneal chemohyperthermia. World J Gastrointest Oncol. 2011;3(12):169-174. https://doi.org/10.4251/wjgo.v3.i12.169
De Simone M, Vaira M, Argenziano M, Berchialla P, Pisacane A, Cinquegrana A, Cavalli R, Borsano A, Robella M. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) with oxaliplatin, cisplatin, and doxorubicin in patients with peritoneal carcinomatosis: an open-label, single-arm, phase II clinical trial. Biomedicines. 2020;8(5):102. https://doi.org/10.3390/biomedicines8050102
Alyami M, Hübner M, Grass F, Bakrin N, Villeneuve L, Laplace N, Passot G, Glehen O, Kepenekian V. Pressurised intraperitoneal aerosol chemotherapy: rationale, evidence, and potential indications. Lancet Oncol. 2019;20(7):e368-e377. https://doi.org/10.1016/S1470-2045(19)30318-3
Mansur A, Gritskievich AA, Kostin AA, Kul’chenko NG, Pospelova OM, Kalinycheva GE. Quality of life of patients with paraurethral cysts. Andrology and Genital Surgery. 2022;23(4):74-80. (In Russ.). https://doi.org/10.17650/2070-9781-2022-23-4-74-80
Li Z, Wong LCK, Sultana R, Lim HJ, Tan JW, Tan QX, Wong JSM, Chia CS, Ong CJ. A systematic review on quality of life (QoL) of patients with peritoneal metastasis (PM) who underwent pressurized intraperitoneal aerosol chemotherapy (PIPAC). Pleura Peritoneum. 2022;7(2):39-49. https://doi.org/10.1515/pp-2021-0154
Odendahl K, Solass W, Demtröder C, Giger-Pabst U, Zieren J, Tempfer C, Reymond MA. Quality of life of patients with end-stage peritoneal metastasis treated with Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC). Eur J Surg Oncol. 2015;41(10):1379-1385. https://doi.org/10.1016/j.ejso.2015.06.001
Willaert W, Van de Sande L, Van Daele E, Van De Putte D, Van Nieuwenhove Y, Pattyn P, Ceelen W. Safety and preliminary efficacy of electrostatic precipitation during pressurized intraperitoneal aerosol chemotherapy (PIPAC) for unresectable carcinomatosis. Eur J Surg Oncol. 2019;45(12):2302-2309. https://doi.org/10.1016/j.ejso.2019.06.018

Close metadata